Weekly Issue — 2026-04-19

In a study published this year in The Journal of Nutrition, researchers led by Keyi Jiao used serum samples from the 2021–2023 cycles of the National Health and Nutrition Examination Survey (NHANES) to construct the first updated U.S. population reference intervals for serum magnesium in roughly half a century. The analytic sample included 787 children and 5,474 adults, and the authors followed the methodology recommended by the International Federation of Clinical Chemistry to derive the new bounds. The headline finding: a contemporary reference interval of 1.70–2.19 mg/dL for boys and 1.64–2.18 mg/dL for girls, with adult intervals stratified by sex, age, and metabolic health.

That may sound like the most inside-baseball revision imaginable. It is not. Serum magnesium is the cheapest, most widely available biomarker for one of the most heavily marketed minerals on the supplement shelf, and the cutoffs your lab uses determine whether your result comes back flagged or shrugged off.

Reference intervals are not laws of nature. They are statistical descriptions of where the middle 95% of an ostensibly healthy population falls on a given test. When the underlying population shifts — in diet, body composition, prevalence of chronic disease, even assay technology — the yardstick drifts out of calibration. The authors note that intervals commonly used in U.S. clinical settings largely reflect data from NHANES I (1971–1974). Fifty years is a long time to keep using the same ruler.

The practical risk runs in both directions. A range that is too generous can wave through people whose magnesium is genuinely depleted. A range built on a healthier past population can also mislabel today's typical reading as suspect. Either way, the lab printout shapes the conversation in the exam room — and increasingly, the algorithm-driven recommendation in your supplement app.

For adolescents, the updated interval landed at 1.70–2.19 mg/dL for boys and 1.64–2.18 mg/dL for girls (0.70–0.90 and 0.68–0.90 mmol/L, respectively). The sex difference in means was statistically significant but small. For adults, the authors stratified by sex, age, and metabolic health status — total population, metabolically healthy, hypertension, diabetes, and chronic kidney disease — which is itself a meaningful methodological choice. A single 'normal' range pretending that a 25-year-old with no conditions and a 70-year-old with type 2 diabetes should fit the same bell curve has always been a polite fiction.

The more clinically pointed finding sits in the subgroup analysis. Mean serum magnesium concentrations were significantly lower in adult males and females with diabetes compared with metabolically healthy adults. That association does not, on its own, tell us whether low magnesium contributes to diabetes, whether diabetes (and its medications) deplete magnesium, or both. It does tell us that a one-size-fits-all reference interval is doing real interpretive work it was never built to do.

Here is the part the supplement aisle would prefer you skip. Serum magnesium is a practical biomarker for assessing nutritional status in clinical settings — emphasis on practical. Roughly speaking, only a small fraction of the body's magnesium circulates in blood; the bulk sits in bone and soft tissue, and the body works hard to keep serum levels stable even when intake is poor. That means a 'normal' serum result can coexist with suboptimal tissue stores, and a 'low normal' result is not automatically a deficiency diagnosis.

None of that makes the new reference intervals less valuable. It makes them more honest. A contemporary, stratified range gives clinicians a better baseline to ask the next question — about diet, medications, kidney function, and metabolic context — rather than a worse one.

The evidence here is moderate, and the claim being graded is narrow: that the U.S. now has a contemporary, methodologically rigorous serum-magnesium reference interval drawn from a large, nationally representative 2021–2023 sample, and that adults with diabetes show lower mean concentrations than metabolically healthy peers. That is what the data support. What they do not support — yet — is a leap from updated lab cutoffs to specific supplementation strategies, dosing, or disease prevention claims. The new ruler is sharper. What you build with it is still up to you and your clinician.

CKM syndrome is the framing the American Heart Association now uses to describe how excess adiposity, insulin resistance, kidney dysfunction and atherosclerotic disease feed each other. It is staged 0 to 4, and most men in midlife sit somewhere in the early stages without knowing it. The problem with conventional risk scoring is that it tends to wait for a single dominant signal — high LDL, high blood pressure, frank diabetes — before sounding the alarm. The CTI takes a different swing: it combines a marker of low-grade inflammation (CRP) with a marker of insulin resistance and lipid handling (the triglyceride-glucose product).

In the China Health and Retirement Longitudinal Study (CHARLS) analysis, researchers pulled data on 7,280 adults from 2011 through 2020. At baseline, participants in the top three CTI quartiles were significantly more likely to already sit in advanced CKM stages than those in the lowest quartile, with a clear dose-response across the distribution. Over a median follow-up of 9.0 years, 1,322 participants — about 21.1% of those starting in CKM stages 0 through 3 — went on to experience a major adverse cardiovascular event.

Each component of the CTI tells a partial story. CRP rises with the smoldering inflammation that quietly remodels artery walls. The triglyceride-glucose index, by now well-validated as a surrogate for insulin resistance, captures how efficiently your body is clearing fuel from the bloodstream. Stacked together, they map two of the core biological currents driving CKM progression — inflammation and metabolic dysfunction — onto a single axis.

The CHARLS team reported that each one-standard-deviation rise in baseline CTI was linked to roughly an 11% higher risk of a major adverse cardiovascular event after adjustment (HR 1.113; 95% CI 1.037–1.195). Cumulative CTI — the integrated exposure across repeat measurements — was also associated with elevated risk per standard deviation (HR 1.030; 95% CI 1.006–1.054). Crucially, the authors found that the composite added prognostic value beyond CRP alone, the TyG index alone, or the two simply reported side-by-side. That incremental signal is the practical case for the score.

Read the numbers honestly. An 11% bump in relative risk per standard deviation is a real signal in a 7,280-person cohort, but it is not a five-alarm fire at the individual level. The CTI's value is not as a verdict; it is as a trend line. If your composite is drifting upward year over year — even while your LDL looks acceptable and your fasting glucose is technically in range — that drift is itself information. The cumulative CTI finding reinforces the point: sustained exposure to a mildly elevated score matters, not just a single bad reading.

There are limits to respect. The cohort is Chinese adults followed in a community survey, not American men in their forties, and CKM trajectories differ across populations, diets and baseline BMI distributions. This is observational work — well-conducted Cox modeling, but not a randomized trial showing that lowering your CTI lowers your event rate. The score has not been validated as a clinical decision tool, and there is no agreed-upon threshold that means "act now." That is why the evidence here rates as moderate, not strong.

What it does do, sensibly, is point at the levers that already have stronger evidence behind them: reducing visceral fat, improving insulin sensitivity through resistance training and aerobic conditioning, tightening sleep and alcohol, and — where indicated — pharmacologic management of lipids, glucose and blood pressure under a clinician's guidance. The CTI is a lens, not a prescription.

The honest summary: the CTI is not a breakthrough biomarker. It is a clever repackaging of three numbers you can already get, weighted in a way that better reflects how cardiometabolic disease actually develops — quietly, on multiple fronts at once. For a generation of men trying to read their own risk before it becomes someone else's diagnosis, that is worth paying attention to. Ask your clinician whether tracking it across your next few panels makes sense. The math is simple. The discipline of watching the trend is the part that matters.

Here's the headline finding, and it deserves a second read. Among more than 9,000 U.S. adults without known cardiovascular disease whose total cholesterol came in under that reassuring 200 mg/dL threshold, roughly 47.5% still had an LDL-C of 100 mg/dL or higher, and about 30.8% had a non-HDL-C of 130 or higher — both numbers that most preventive cardiologists would flag as worth a conversation. Scaled up using the survey weights, that's tens of millions of adults walking around with a 'normal' top-line score and an atherogenic cholesterol picture that isn't actually normal at all.

The reason this happens is unglamorous arithmetic. Total cholesterol is a sum: LDL plus HDL plus a chunk derived from triglycerides. If your HDL is robust, it can pad the total upward in a way that looks neutral but isn't — your LDL can still be elevated underneath. And if your triglycerides are creeping (a very common perimenopausal pattern), non-HDL-C — which is just total cholesterol minus HDL, and captures every artery-irritating particle in one number — can quietly drift into risk territory while the headline figure stays polite.

If you've ever asked for a copy of your labs (and you should), you've seen non-HDL-C sitting there, usually un-highlighted, while LDL gets all the attention. The NHANES authors argue it deserves a promotion. Their data show that elevated LDL-C or non-HDL-C clustered most heavily in the people you'd expect to be most metabolically vulnerable — those with elevated triglycerides or metabolic syndrome. In other words, the very women who are told their cholesterol is 'fine' are sometimes the ones whose atherogenic particles are doing the most quiet work.

There's a reassuring counterpoint in the same dataset, though: no participant with a total cholesterol under 150 mg/dL had an elevated LDL-C or non-HDL-C. So a genuinely low total really is low. It's the 150-to-199 zone — the unglamorous middle — where the hidden math lives.

The second study worth pulling onto the table doesn't measure cholesterol at all — it measures the metabolic terrain that decides how much trouble your cholesterol will cause. Researchers using the long-running China Health and Retirement Longitudinal Study followed several thousand middle-aged and older adults and tested whether combining two cheap, calculable indices — the triglyceride-glucose (TyG) index, a proxy for insulin resistance, and the Chinese Visceral Adiposity Index (CVAI), a proxy for the deep belly fat that wraps your organs — would do a better job of predicting cardiovascular events than the usual suspects.

It did, modestly but consistently. Adults in the highest baseline TyG-CVAI category, and those whose levels stayed elevated over time, had meaningfully higher risk of cardiovascular disease — with hazard ratios of 1.61 and 1.68 respectively. Adding the combined index improved risk reclassification for CVD, coronary heart disease, and stroke beyond standard markers, with area-under-the-curve values in the high 0.5s — not a crystal ball, but a sharper lens.

A caveat worth naming out loud: this cohort was Chinese, middle-aged and older, and the CVAI was developed specifically for that population. Whether the same composite performs identically in American women in their 40s is an open question. But the underlying logic — that insulin resistance and visceral fat together tell you more than either lipid or glucose alone — lines up neatly with what the NHANES paper is hinting at from the other direction.

Two studies don't rewrite a guideline. The evidence here is moderate: large, well-conducted observational datasets, consistent with a growing body of work, but not randomized trials proving that acting on non-HDL-C or TyG-CVAI changes outcomes. What they do is sharpen a question you can bring to your own clinician — particularly if you're in the perimenopausal window, when LDL and triglycerides tend to rise even when nothing else in your life has changed.

That question is roughly: given my total cholesterol, what do my LDL-C and non-HDL-C actually look like, and do they fit with my waist circumference, fasting glucose, and triglycerides? It's a more honest framing than 'is my cholesterol okay,' because it treats your cardiovascular risk as the multi-variable thing it actually is rather than a single number on a sticker.

None of this is a prescription. It isn't a reason to panic-buy a statin online or to start fasting yourself into a different lipid panel. It's a reason to ask for the numbers under the number — and to take the answer seriously even when the headline looks clean.